RxDoctor Payments Data

Hang Ruzycki

Nurse Practitioner · Ann Arbor, MINPI 1730794330

Payments from drug & device makers

$1,079in general payments, 2019–2025

Across 30 payments — averaging $35.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$483
  • Antares Pharma, Inc.$183
  • Astellas Pharma US Inc$98
  • Tolmar, Inc.$69
  • Endo Pharmaceuticals Inc.$55
  • Tolmar Pharmaceuticals, Inc.$53
  • plus $137 from 4 others

What the payments were for

  • Travel & lodging$46543%
  • Food & beverage$59655%
  • Education$182%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,079 in reported general payments places this provider in the 80th percentile of 3,351 nurse practitioner providers in Michigan.

See all nurse practitioner providers in Michigan

Medicare billing

Part B allowed, 2024
$38,093
Medicare patients
259
Services billed
823

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron170$153,432
Mirabegron ErMirabegron44$26,369
Estradiol118$12,249
Trospium Chloride ErTrospium Chloride34$9,725
EliquisApixaban11$8,243
Tamsulosin Hcl319$6,674
Methenamine Hippurate88$6,191
Fosfomycin Tromethamine28$5,254
Tolterodine Tartrate ErTolterodine Tartrate44$3,992
YuvafemEstradiol16$3,011
Trospium Chloride16$1,640
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst89$1,439
Finasteride76$1,417
Gentamicin Sulfate35$1,367
Trimethoprim14$907

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$98$153,432170 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,351 nurse practitioner providers in Michigan.

Other nurse practitioner in Ann Arbor

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →